DMP Stock Overview
Manufactures and sells off-patent branded pharmaceutical products in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Dermapharm Holding SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €36.90 |
| 52 Week High | €43.22 |
| 52 Week Low | €30.15 |
| Beta | 1.14 |
| 11 Month Change | 13.89% |
| 3 Month Change | 2.93% |
| 1 Year Change | -8.16% |
| 33 Year Change | -53.41% |
| 5 Year Change | -3.07% |
| Change since IPO | 41.92% |
Recent News & Updates
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28
Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17Recent updates
Here's Why Dermapharm Holding (ETR:DMP) Has A Meaningful Debt Burden
Sep 28Dermapharm Holding SE Beat Revenue Forecasts By 6.7%: Here's What Analysts Are Forecasting Next
Aug 31Dermapharm Holding SE's (ETR:DMP) P/E Still Appears To Be Reasonable
Aug 17It Looks Like Dermapharm Holding SE's (ETR:DMP) CEO May Expect Their Salary To Be Put Under The Microscope
Jun 21These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Extensively
Apr 29Dermapharm Holding SE's (ETR:DMP) Price In Tune With Earnings
Feb 07Dermapharm Holding (ETR:DMP) Seems To Use Debt Quite Sensibly
Dec 15An Intrinsic Calculation For Dermapharm Holding SE (ETR:DMP) Suggests It's 24% Undervalued
Nov 17Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
Aug 28Dermapharm Holding SE's (ETR:DMP) Intrinsic Value Is Potentially 76% Above Its Share Price
Aug 01Dermapharm Holding (ETR:DMP) Has A Pretty Healthy Balance Sheet
May 29Is Dermapharm Holding SE (ETR:DMP) Trading At A 44% Discount?
May 03Dermapharm Holding's (ETR:DMP) Soft Earnings Are Actually Better Than They Appear
Apr 04We Think Dermapharm Holding (ETR:DMP) Can Stay On Top Of Its Debt
Feb 22Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Nov 17Is Dermapharm Holding (ETR:DMP) A Risky Investment?
Aug 16Is Dermapharm Holding (ETR:DMP) A Risky Investment?
May 18Is Dermapharm Holding (ETR:DMP) Using Too Much Debt?
Feb 17These 4 Measures Indicate That Dermapharm Holding (ETR:DMP) Is Using Debt Reasonably Well
Nov 19Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Aug 21Is Dermapharm Holding SE (ETR:DMP) Trading At A 28% Discount?
Jul 31Is Dermapharm Holding SE (ETR:DMP) The Right Choice For A Smart Dividend Investor?
May 03Calculating The Intrinsic Value Of Dermapharm Holding SE (ETR:DMP)
Apr 16Here's Why Dermapharm Holding (ETR:DMP) Can Manage Its Debt Responsibly
Mar 25Did You Miss Dermapharm Holding's (ETR:DMP) Impressive 110% Share Price Gain?
Mar 07Is Dermapharm Holding SE's (ETR:DMP) 27% ROE Better Than Average?
Feb 15Something To Consider Before Buying Dermapharm Holding SE (ETR:DMP) For The 1.4% Dividend
Jan 29Does Dermapharm Holding (ETR:DMP) Have A Healthy Balance Sheet?
Dec 24
The Dermapharm Holding (ETR:DMP) Share Price Has Gained 45% And Shareholders Are Hoping For More
Dec 07Dermapharm Holding SE Just Missed Earnings - But Analysts Have Updated Their Models
Nov 18Shareholder Returns
| DMP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 17.9% | -7.0% | -0.4% |
| 1Y | -8.2% | -21.6% | 7.1% |
Return vs Industry: DMP exceeded the German Pharmaceuticals industry which returned -22.4% over the past year.
Return vs Market: DMP underperformed the German Market which returned 7.8% over the past year.
Price Volatility
| DMP volatility | |
|---|---|
| DMP Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: DMP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: DMP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 3,603 | Hans-Georg Feldmeier | ir.dermapharm.de |
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany. The company operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. It offers branded generics, OTC products, non-prescription healthcare products, and herbal extracts and parallel-imported originator pharmaceuticals.
Dermapharm Holding SE Fundamentals Summary
| DMP fundamental statistics | |
|---|---|
| Market cap | €1.99b |
| Earnings (TTM) | €90.59m |
| Revenue (TTM) | €1.18b |
21.9x
P/E Ratio1.7x
P/S RatioIs DMP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMP income statement (TTM) | |
|---|---|
| Revenue | €1.18b |
| Cost of Revenue | €439.61m |
| Gross Profit | €736.26m |
| Other Expenses | €645.68m |
| Earnings | €90.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 62.61% |
| Net Profit Margin | 7.70% |
| Debt/Equity Ratio | 174.1% |
How did DMP perform over the long term?
See historical performance and comparison